Skip to main content

Advertisement

SpringerLink
Log in

Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines

  • Original Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Despite recent advances in the application of chemotherapy to ovarian cancer, the development of alternative therapies that retain activity against drug-resistant-tumors remains a high priority. We analyzed a number of cultured ovarian cancer cell lines of different tissue types for the presence or absence of sensitivity to various anticancer drugs as well as expression patterns of oncogene products (erbB-2, EGFR, bcl-2). As a result, we identified oncogene products that were related to resistance. Using 9 cultured cell lines of ovarian cancers (serous, mucinous, endometrioid, clear, undifferentiated), sensitivities to anticancer drugs were investigated using the MTT assay. The phenotypes of oncogene products expressed by the above cultured cell lines were analyzed by Western blotting. The oncogene products involved in resistance to anticancer drugs were identified by multivariate analysis. Positive correlation between the resistance to anticancer drugs and the oncogene products was obtained by multivariate analysis for (a) CDDP and erbB-2 (b) · p-16 and erbB-2, and (c) MMC and EGFR. Correlation between resistance to anticancer drugs and expression of certain oncogene products was obtained in ovarian cancers, suggesting that sensitivity to anticancer drugs could be predicated prior to chemotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ishiwata I, Ishiwata C, Ishikawa H, et al.: Characterization of newly established human ovarian carcinoma cell line—special reference of the effects of cis-platinum of cellular proliferation and release of CAl25. Gynecol Oncol 26: 340–354, 1987.

    Article  PubMed  CAS  Google Scholar 

  2. Gorai I, Nakazawa T, Minaguchi H, et al.: Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties. Gynecol Oncol 57: 33–46, 1995.

    Article  PubMed  CAS  Google Scholar 

  3. Nozawa S, Tsukazaki K, Iizuka R, et al.: Establishment of human ovarian clear cell carcinoma cell line (RMG-1) and its single cell cloning—With special reference to the stem cell of the tumor. HUMAN CELL 1: 426–435, 1988.

    PubMed  CAS  Google Scholar 

  4. Kidera Y, Yoshimura T, Sugimori H, et al.: Establishment and characterization of a cell line derived from mucinous cystadenocarcinoma of human ovary. Nippon Sanka Fujinka Gakkai Zasshi 37: 1820–1824, 1985.

    PubMed  CAS  Google Scholar 

  5. Ishiwata I, Ishiwata C, Ishikawa H, et al.: Establishment and characterization of Two Human Ovarian Endometrioid Carcinoma Cell Lines. (with or without Squamous cell Component) Gynecol Oncol 25: 95–107, 1986.

    Article  PubMed  CAS  Google Scholar 

  6. Ishiwata I, Ishiwata C, Ishikawa H, et al.: Establishment and characterization of a Human Ovarian Anaplastic Carcinoma Cell Line. Gynecol Oncol 30: 35–43, 1988.

    Article  PubMed  CAS  Google Scholar 

  7. Sakamoto H: Molecular Biology of Multidrug Resistance (MDR) in Ovarian cancers and Novel Method of Detecting MDR In Vitro. Acta. Obst. Gynaec Jpn 51: 549–561, 1999.

    CAS  Google Scholar 

  8. Klemi PJ, Pylkkanen L, Joensuu H: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201–1208, 1995.

    Article  PubMed  CAS  Google Scholar 

  9. Herod JJ, Elipoulos AG, Kerr DJ: The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178–2184, 1996.

    PubMed  CAS  Google Scholar 

  10. Oltvai ZN, Milliman CL, Korsmeter SJ: Bcl-2 heterodimerizes in vivo with a Conserved homolog, Bax, that Accelerates programmed cell death. Cell 74: 609–619, 1993.

    Article  PubMed  CAS  Google Scholar 

  11. Eliopoulos AG, Kerr DJ, Herod JJ, et al.: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 11: 1217–1228, 1995.

    PubMed  CAS  Google Scholar 

  12. Ishioka S, Sagae S, Kudo R Antidrug resistance and Apoptosis in ovarian cancers. Sanfujinkanojissai 47: 1871–1876, 1998.

    Google Scholar 

  13. Aunoble B, Sanches R, Bignon YJ, et al.: Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (Review). Int. J. Oncology 16: 567–576, 2000.

    CAS  Google Scholar 

  14. Scambia G, Benedetti PP, Mancuso S, et al.: Expression of HER-2/neu oncoprotein, DNA-ploidy and S-phase fraction in advanced ovarian cancer. Int Gynaecol Cancer 3: 271–278, 1993.

    Article  Google Scholar 

  15. Slamon DJ, Godolphin W, Jones L, et al.: Study of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 513–516, 1984.

    Google Scholar 

  16. Slamon DJ, Clark G, Wong S, et al.: Human breast correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–181, 1987.

    Article  PubMed  CAS  Google Scholar 

  17. Mark DP, Richard SF, Dennis JS, et al.: The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 15: 537–547, 1997.

    Article  Google Scholar 

  18. Menden H, Marx D, Kuhn W, et al.: EGF-R and Overexpression of the Oncogene C-erbB-2 in Ovarian Cancer: Immunohistchemical Findings and Prognostic Value. J. Obstet. Gynaecol 21: 167–178, 1995.

    Google Scholar 

  19. Berchuck A, Kame1 A, Bast RC, et al.: Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer: Cancer Res 50: 4087–4091, 1990.

    PubMed  CAS  Google Scholar 

  20. Hengstler JG, Lange S, Tanner B, et al.: Contribution of c-erb B-2 and Topoisomerase II α to Chemoresistance in Ovarian Cancer. Cancer Res 59: 3206–3214, 1999.

    PubMed  CAS  Google Scholar 

  21. Reese DM, Slamon DJ: HER-2/neu Signal Transduction in Human Breast and Ovarian Cancer. Stem Cells 15: 1–8, 1997.

    Article  PubMed  CAS  Google Scholar 

  22. Togo A. DNA Topoisomerase I inhibitor: DX-8951F(Exatecan Mesylate). New trial to cancer therapy II: 38–48.

  23. Tsai CM, Chang KT, Perng RP, et al.: Correlation of intrinsic chemoresistance of non small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85: 897–901, 1993.

    Article  PubMed  CAS  Google Scholar 

  24. Aigner A, Hsieh SS, et al.: Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistance to taxol. Toxicology 144: 221–228, 2000.

    Article  PubMed  CAS  Google Scholar 

  25. Yamamoto N: Drugs ∼. New trial to cancer therapy II: 55–68.

  26. Richard AB, Sherry P, Deborah M, et al.: Raf-1 kinae activity predicts for paclitaxel resistance in TP53mut, but not TP53wt human ovarian cancer cells. Oncol Rep 7: 821–825, 2000.

    Google Scholar 

  27. Blagosklonny MV, Schulte T, Neckers LM, et al.: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represent a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851–1854, 1996.

    PubMed  CAS  Google Scholar 

  28. Kroemer G, Petit P, Zamzami N, et al.: The biochemistry of programmed cell death. FASEB J 9: 1277–1287, 1995.

    PubMed  CAS  Google Scholar 

  29. Kiyomiya H, Tsuruo T Anticancer Drugs and Apoptosis. Bio. Clin 12: 686–690, 1997.

    Google Scholar 

  30. Kita T, Kudo K, Kikuchi Y: Mechanisms of resistance to anticancer drugs in gynecologic cancers. Comprehensive Handbook of Women’s Medicine 41: 313–324, 2001.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Japan

    Yoshiaki Okuma, Kazushige Kiguchi, Asami Okamura, Haruhiro Kondo & Bunpei Ishizuka

  2. Department of Pathology, Machida Municipal Hospital, Japan

    Yutaka Koshitaka

  3. Ishiwata Obstetrics and Gynecology Hospital, Japan

    Isamu Ishiwata

  4. Department of Pathology, St. Marianna University School of Medicine, Japan

    Mamoru Tadokoro

Authors
  1. Yoshiaki Okuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazushige Kiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yutaka Koshitaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Asami Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isamu Ishiwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haruhiro Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bunpei Ishizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mamoru Tadokoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okuma, Y., Kiguchi, K., Koshitaka, Y. et al. Correlation between expression of oncogene products and resistance to anticancer drugs in cultured ovarian cancer cell lines. Hum Cell 16, 131–139 (2003). https://doi.org/10.1111/j.1749-0774.2003.tb00145.x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1111/j.1749-0774.2003.tb00145.x

Key words

Search

Navigation